



The 65th ASH Annual Meeting Abstracts

ONLINE PUBLICATION ONLY

703.CELLULAR IMMUNOTHERAPIES: BASIC AND TRANSLATIONAL

CAR-T Cells for Systemic Lupus Erythematosus

Matteo Doglio, MD¹, Alessia Ugolini², Clara Bercher², Cristiano Toma², Chiara Bonini, MD³, Fabio Ciceri^{4,5}, Barbara Camisa⁶, Rossana Norata⁷, Stefania Del Rosso⁸, Francesca Sanvito⁹, Monica Casucci, PhD¹⁰, Angelo Manfredi¹¹

¹IRCCS San Raffaele Scientific Institute, Milano, Italy

²IRCCS Vita-Salute San Raffaele University, Milan, Italy

³OSPEDALE SAN RAFFAELE, Milano, Italy

⁴Unit of Hematology and Stem Cell Transplantation, Ospedale San Raffaele, University Vita-Salute San Raffaele, Milan, Italy

⁵University Vita-Salute, IRCCS Ospedale San Raffaele, Haematology and BMT, Milan, Italy

⁶San Raffaele Scientific Institute, Milan, ITA

⁷IRCCS San Raffaele Scientific Institute, Milano, ITA

⁸IRCCS San Raffaele Hospital, Milan, Italy

⁹San Raffaele Scientific Institute, Milano, ITA

¹⁰San Raffaele Scientific Institute Stem Cells and Gene Therapy, Milan, ITA

¹¹H San Raffaele University, Milan, ITA

Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by an abnormal inflammatory response against nuclear antigens with consequent tissue damage. Autoreactive B cells and auto-antibodies have a fundamental role in SLE pathogenesis. Lupus nephritis (LN) has a great impact on patients' survival and quality of life and still represents an unmet clinical need due to the lack of specific treatments and to the poor response to conventional immunosuppression. Regulatory T cells (Tregs) physiologically maintain the immune tolerance and are impaired in SLE. Polyclonal Treg transfer obtained unsatisfactory results due to the low number of disease-relevant antigen-specific cells. Chimeric Antigen Receptors (CARs) are molecules capable of redirecting T cell specificity. CAR-Tregs proved effective in pre-clinical mouse models of autoimmunity. We aimed at developing a CAR-Treg based product to be employed in SLE in particular in LN.

We isolated Tregs from Healthy Donors Peripheral Blood Mononuclear Cells (PBMCs) and expanded them with IL-2 and rapamycin. We transduced Tregs with a Lentiviral Vector encoding for a second-generation anti-CD19 CAR, considering the relevant role of autoreactive B cells and autoantibodies in SLE. Engineered cells retained their immune suppressive capabilities upon polyclonal stimulation. Noticeably, they acquired new antigen-specific suppressive capacities, being able to block autologous B cell proliferation. We set up a humanized mouse model of SLE. In vivo, CAR-Tregs delayed the occurrence of B cell lymphopenia, producing immunomodulatory cytokines and without showing toxicity or reprogramming towards Th17 pro-inflammatory cells. In inflamed organs, CAR-Tregs restored the normal composition of the immune system.

In conclusion, we efficiently generated anti-CD19 CAR-Tregs and proved their efficacy both in vitro and in an in vivo humanized mouse model of lupus.

Disclosures Bonini: INTELLIA THERAPEUTICS: Membership on an entity's Board of Directors or advisory committees, Research Funding; ALIA THERAPEUTICS: Membership on an entity's Board of Directors or advisory committees; GENYO: Membership on an entity's Board of Directors or advisory committees; CHROMA: Consultancy; PAN CANCER: Membership on an entity's Board of Directors or advisory committees; SMART IMMUNE: Membership on an entity's Board of Directors or advisory committees. **Ciceri:** ExCellThera: Other: Scientific Advisory Board .

<https://doi.org/10.1182/blood-2023-189673>